AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
Financing agreement to pre-finance the 2019 research tax credit
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
Webcast on indolent systemic mastocytosis on November 20, 2019
04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019
Authorization to initiate phase 3 confirmatory study in mastocytosis
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
Update on masitinib programs timelines
10/10/2019 – AB Science provides update on masitinib programs timelines
First half of 2019 results
30/09/2019 – AB Science reports its revenues for the first half of 2019
10M€ raised through a private placement
19/08/2019 – AB Science announces the success of a private placement
AB Science to present at two upcoming conferences in September 2019
12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
Update on masitinib clinical program
05/08/2019 – AB Science provides an update on its masitinib clinical program.